Grape King Bio Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Grape King Bio.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth	18.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

Recent updates

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Feb 27

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Nov 20

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grape King Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1707 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	11,205	1,470	1,590	2,313	N/A
6/30/2024	10,857	1,421	1,000	1,632	N/A
3/31/2024	10,763	1,431	1,954	2,550	N/A
12/31/2023	10,635	1,453	1,918	2,519	N/A
9/30/2023	10,559	1,456	2,019	2,571	N/A
6/30/2023	10,501	1,454	2,182	2,776	N/A
3/31/2023	10,558	1,501	2,410	2,977	N/A
12/31/2022	10,391	1,457	2,488	2,990	N/A
9/30/2022	10,186	1,426	2,287	2,664	N/A
6/30/2022	10,097	1,363	2,725	3,066	N/A
3/31/2022	9,879	1,304	2,218	2,539	N/A
12/31/2021	9,798	1,300	2,264	2,542	N/A
9/30/2021	9,623	1,281	2,320	2,590	N/A
6/30/2021	9,387	1,283	2,305	2,558	N/A
3/31/2021	9,131	1,242	1,683	2,669	N/A
12/31/2020	9,168	1,272	1,493	2,719	N/A
9/30/2020	9,138	1,279	1,264	2,507	N/A
6/30/2020	9,082	1,280	1,121	2,444	N/A
3/31/2020	9,234	1,309	1,570	2,185	N/A
12/31/2019	9,239	1,309	1,516	2,171	N/A
9/30/2019	9,193	1,288	1,296	2,146	N/A
6/30/2019	9,303	1,323	1,631	2,685	N/A
3/31/2019	9,265	1,298	1,310	2,415	N/A
12/31/2018	9,183	1,295	1,296	2,417	N/A
9/30/2018	9,302	1,331	1,432	2,450	N/A
6/30/2018	9,325	1,322	N/A	2,245	N/A
3/31/2018	9,317	1,353	N/A	2,183	N/A
12/31/2017	9,388	1,352	N/A	2,496	N/A
9/30/2017	9,130	1,295	N/A	2,310	N/A
6/30/2017	9,183	1,298	N/A	2,409	N/A
3/31/2017	9,180	1,272	N/A	2,790	N/A
12/31/2016	9,185	1,297	N/A	2,803	N/A
9/30/2016	8,667	1,219	N/A	2,737	N/A
6/30/2016	8,099	1,148	N/A	1,475	N/A
3/31/2016	7,606	1,097	N/A	1,486	N/A
12/31/2015	7,248	1,052	N/A	1,307	N/A
9/30/2015	6,995	1,035	N/A	1,197	N/A
6/30/2015	6,777	1,019	N/A	2,567	N/A
3/31/2015	6,548	986	N/A	2,053	N/A
12/31/2014	6,283	942	N/A	1,922	N/A
9/30/2014	6,038	907	N/A	1,760	N/A
6/30/2014	5,913	867	N/A	1,140	N/A
3/31/2014	5,797	857	N/A	1,479	N/A
12/31/2013	5,639	836	N/A	1,576	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1707's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 1707's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1707's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1707's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1707's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1707's Return on Equity is forecast to be high in 3 years time

Grape King Bio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 12% to NT$170

Price target decreased to NT$195

Price target lowered to NT$206

Recent updates

Now 20% undervalued

Third quarter 2024 earnings released: EPS: NT$2.81 (vs NT$2.48 in 3Q 2023)

Grape King Bio Ltd to Report Q3, 2024 Results on Nov 11, 2024

Now 21% overvalued

Second quarter 2024 earnings: EPS misses analyst expectations

Grape King Bio Ltd Announces Changes to Remuneration Committee

Grape King Bio Ltd to Report Q2, 2024 Results on Aug 12, 2024

Grape King Bio's (TWSE:1707) Dividend Will Be NT$6.90

Upcoming dividend of NT$6.90 per share

Grape King Bio (TWSE:1707) Will Pay A Dividend Of NT$6.90

Dividend of NT$6.90 announced

Grape King Bio Ltd Approves Changes to the Board

Grape King Bio Ltd Announces Dividend, Payable on July 18, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Grape King Bio Ltd to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Price target decreased by 12% to NT$170

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Upcoming dividend of NT$6.90 per share at 3.9% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% undervalued after recent price drop

Now 21% undervalued

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of NT$6.10 per share

Grape King Bio Ltd Announces Cash Dividend

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Grape King Bio Ltd Applies to FDA for A Phase II Clinical Trial Review in Humans for GKAC

Third quarter 2021 earnings released: EPS NT$2.04 (vs NT$2.23 in 3Q 2020)

Price target decreased to NT$195

Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$2.09 in 2Q 2020)

Upcoming dividend of NT$6.40 per share

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

Grape King Bio (TPE:1707) Knows How To Allocate Capital

Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Grape King Bio's (TPE:1707) Anemic Earnings Might Be Worse Than You Think

Revenue beats expectations

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Full year 2020 earnings released: EPS NT$9.34 (vs NT$9.63 in FY 2019)

Grape King Bio Ltd, Annual General Meeting, May 28, 2021

New 90-day high: NT$181

Grape King Bio Ltd announced that it expects to receive TWD 2.01467 billion in funding from Uni-President Enterprises Corp.

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Price target lowered to NT$206

Third quarter 2020 earnings released: EPS NT$2.23

Earnings beat expectations, revenue disappoints

New 90-day low: NT$167

New 90-day low: NT$176

New 90-day low - NT$178

New 90-day low - NT$184

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies